U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07541469) titled 'Rezdiffra Pregnancy and Lactation Registry' on March 19.
Brief Summary: To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.
Study Start Date: March 04
Study Type: OBSERVATIONAL
Condition:
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Intervention:
DRUG: Rezdiffra
Exposure to at least one dose of Resmetirom.
Recruitment Status: RECRUITING
Sponsor: Madrigal Pharmaceuticals, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....